ArticleVeterinary ophthalmology2026
Feasibility and Safety of Argon Cold Plasma Use as an Adjunctive Treatment for Corneal Disease in Dogs, Cats and Small Mammals: A Prospective Clinical Study.
Article in Veterinary ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibiotics in Veterinary Ophthalmology: Resistance, Stewardship, and Emerging Antibiotic-Sparing Strategies.Veterinary ophthalmology · 2026Review
- Feasibility and Safety of Argon Cold Plasma Use as an Adjunctive Treatment for Corneal Disease in Dogs, Cats and Small Mammals: A Prospective Clinical Study.Veterinary ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEvaluation of the feasibility of argon cold plasma (ACP) use in corneal diseases in clinical practice and assessment of short- and long-term safety in dogs, cats, and small mammals. ANIMALS STUDIED: Client-owned animals. PROCEDURE: ACP was performed in animals with corneal diseases using the kINPenVET (Neoplas GmbH, Germany) under topical anesthesia as an adjunct to standard treatment. Early (< 30 days) and long-term (> 30 days) adverse reactions and events were monitored.
results303 eyes in 281 animals were treated with ACP (263 dogs, 8 cats, 10 small mammals) with the following conditions: spontaneous chronic corneal epithelial defects (SCCED, n = 178), infected/infiltrated ulcers (n = 76), keratomalacia (n = 22), corneal perforation (n = 20), other (n = 7). Treatment under topical anesthesia was well tolerated with only a few animals showing stress during the procedure (3.2%, 8 dogs, 1 cat). The average number of treatments per eye was 3.45 ± 1.74 with a median of 3 (1-9). The two direct adverse reactions observed were punctate opacities (1.3%, n = 4) and blepharospasm (0.7%, n = 2). Short-term adverse events were: epithelial tears differing from the initial ulceration (4.0%, n = 12), development of stromal infiltrates (2.3%, n = 7), occurring/persistent keratomalacia (2.0%, n = 6). Long-term follow-up period averaged 173.1 days with a median of 117 (30-619) days. The most common long-term adverse events were significant corneal fibrosis and pigmentation (4.0%, n = 12, mostly cases of dry eyes).
conclusionsACP with kINPenVET is a clinically feasible outpatient treatment for various corneal diseases with a low number of short- and long-term adverse reactions and events. It can be easily integrated into clinical treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.